PET-FDG as predictor of therapy response in patients with colorectal carcinoma

Quarterly Journal of Nuclear Medicine

Volumn 47, Issue 1, 2003, Pages 8-13

  Dimitrakopoulou Strauss, A ^a   Strauss, L G ^a   Rudi, J ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Colonic neoplasms, radionuclide imaging; Fludeoxyglucose F18; Rectal neoplasms, radionuclide imaging; Tomography, emission computed

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ANALYTICAL PARAMETERS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DRUG RESPONSE; EVALUATION; FOLLOW UP; HUMAN; KINETICS; METASTASIS; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0038354700     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. 18F-FDG-PET on managing patients with colorectal cancer: The referring physician's perspective. J Nucl Med 2001;42:586-90.
2. Gambhir SS, Czernin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1-93S.
3. Engenhart R, Kimmig BN, Strauss LG, Hover KH, Romahn J, Haberkorn U et al. Therapy monitoring of presacral recurrences after high-dose irradiation: Value of PET, CT, CEA and pain score. Strahlenther Onkol 1992;168:203-12.
4. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T et al. Noninvasive monitoring or tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal liver metastases; Correlation with tumor response to fluorouracil. J Clin Oncol 1996;14:700-8.
5. Kemeny N. The systematic chemotherapy of hepatic metastases. Semin Oncol 1983;10:148-58.
6. Heidelberger C. On the rational development of a new drug: The example of the fluorinated pyrimidines. Cancer Treat Rep 1981;65:3-9.
7. Bleiberg H, De Gramont A. Oxaliplatin plus 5-fluorouracil: Clinical experience in patients with advanced colorectal cancer. Semin Oncol 1998;224:509-22.
8. Machover D, Diaz-Rubio E, De Gramont A, Schilf A, Gastiaburu JJ, Brienza S et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-8.
9. 18F)fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. Nucl Med Biol 1990;3:273-9.
10. Kontaxakis G, Strauss LG, Tzanakos GS. An efficient implementation of the iterative ML-EM image reconstruction algorithm for PET on a Pentium PC platform. J Comput Inform Technol-CIT 1999;7:153-63.
11. Strauss LG, Kontaxakis G, Dimitrakopoulou-Strauss A. Performance characteristics of iterative image reconstruction for routine use in positron emission tomography. Alasbimn 3: October 2001. www.alasbimnjournal.cl/revistas/13/strauss.html
12. Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C. A Java environment for medical image data analysis: Initial application for brain PET quantitation. Med Inform 1998;23:207-14.
13. Burger C, Buck A. Requirements and implementations of a flexible kinetic modeling tool. J Nucl Med 1997;38:1818-23.
14. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-48.
15. Peitgen HO, Juergens H, Saupe D. Chaos and Fractals. New York, USA: Springer, 1992.
16. Kleen M, Habler O, Zwissler B, Messmer K. Programs for assessment of spatial heterogeneity of regional organ blood flow. Comput Methods Programs Biomed 1998;55:51-7.
17. Dimitrakopoulou-Strauss A, Strauss LG, Burger C. Fractal dimension: A new parameter for the quantification of dynamic PET studies. Eur J Nucl Med 2001;28:1065P [abstract].
18. Dimitrakopoulou-Strauss A, Straus LG, Schlag P, Hohenberger P, Mohler M, Oberdorfer F et al. Fluorine-18-Fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 1998;39:1197-202.
19. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer 1998;83:245-53.
20. Devesa SS, Silverman DT, Young JL Jr, Pollak ES, Brown CC, Horm JW et al. Cancer incidence and mortality trends among whites in the United States, 1947-1984. J Natl Cancer Inst 1987;79:701-70.
21. Cremerius U, Fabry U, Neuerburg J, Zimny M, Bares R, Osieka R et al. Prognostic significance of positron emission tomography using fluorine-18-fluordeoxyglucose in patients treated for malignant lymphoma. Nuklearmedizin 2001;40:23-30.
22. Strauss LG, Dimitrakopoulou-Strauss A, Koomaegi R, Zhang Y, Schwarzbach M, Heichel T. Metabolic activity and multidrug resistance in sarcomas. J Nucl Med 2000;41:288P [abstract].